BK

🚀 Hidden Gems

📈 Value Investor
💡 | Macro view | Long-Term Wealth

🔔 market trends & #ValueInvesting #HiddenGems #MultibaggerHunt

[BK @bk7gems]

Kalyani Cast-Tech Ltd is a specialised manufacturer of cargo containers & castings, with a growing integrated logistics platform. It focuses on non-commodity products tailored to Indian Railways (IR) constraints rather than pure ISO dry boxes. FY26 revenue was ~₹150–152 Cr (+~8% YoY) with PAT ~₹17 Cr (+~20%), high ROCE (~28%), and a near debt-free balance sheet. Market cap is ~₹800 Cr at ~₹1,115 (TTM P/E ~47–54x).

Competitive Advantages

Founder-led innovation is the key differentiator. CMD Naresh Kumar (IIT Madras, ex-IRSME with 17 years including senior roles at CONCOR and a major wagon/coach unit) holds more than five patents. Multiple company & industry sources state the firm holds four patents in container manufacturing. He is widely recognised as the pioneer (“father of multi-stack trains”) of the Double Stack Dwarf Container (DSDC) concept.

Dwarf Container advantages (the flagship IP):
•Lower height (~1930 mm / 6’4”) and wider (2600 mm) design allows double-stacking under standard overhead electrification on most/all IR routes, something standard ISO double-stack cannot do outside limited corridors (mainly Western DFC).
•Delivers ~67% higher volume when double-stacked versus single ISO, higher payload capacity (e.g., ~71 tonnes combined vs ~40 tonnes for typical ISO), and 20–50% lower unit transport costs for light/medium-density cargo.
•Enables capture of higher-value or lower-density freight (petrochemicals, FMCG, plastics, etc.) from road to rail. IR has issued policy circulars for DSDC operations and offered haulage discounts; commercial services have run since 2018 (e.g., from ports like JNPT).

Supporting proprietary elements include special composite/FRP flooring (lighter and thinner than traditional, claimed as a first-in-world application for this use) & custom corner castings suited to the wider dwarf design.

Hard-to-replicate advantages:
•Only Indian foundry approved by Lloyd’s Register UK for container corner fittings (a critical structural/safety component under international rules). This is a meaningful barrier.
•RDSO Class A foundry status and Indian Register of Shipping approvals for containers.
•Deep institutional relationships & regulatory know-how from the founder’s IR career, which facilitated design clearances, trials, and commercialisation.
•In-house design-to-manufacture capability for custom solutions (foldable containers, stainless-steel bulk containers for salt/steel products, cuboid containers for LTL/parcel cargo, etc.). Recent developments include stainless-steel salt containers (RDSO-advised trials) and a partnership for IceBattery reefer technology.
•Emerging vertical integration: specialised containers + new wagon designs (with Ministry/RDSO in-principle approvals) + Gati Shakti terminal + ICD in Kutch, Gujarat (near ports). This can create captive demand and cost advantages.

These elements create a practical moat in specialised/non-commoditised containers. The combination of design IP, regulatory approvals, first-mover status & relationships provides differentiation & supports higher margins versus generic assemblers. The co has already manufactured thousands of containers and driven meaningful import substitution.

Valuation Context
Tailwinds include IR’s freight modernisation & double-stack push, rising containerised traffic & the ₹10k Cr govt scheme for container manufacturing (we produce a tiny fraction of global/Chinese output). Gujarat capacity ramp (containers operational, terminal inaugurated, wagons targeted H2 FY27) plus specialised products can drive operating leverage.

At ~50x TTM earnings, the valuation prices in continued growth. Upside depends on successful wagon/terminal ramp, higher specialised-container mix & utilisation.

Recent periods show moderation consistent with expansion & make-to-order dynamics.

Key Risks
Execution risk on large relative capex & RDSO/wagon approvals; competition as policy incentives attract more players etc.,

[BK @bk7gems]

@elonmusk @cb_doge This is not so you Elon … wake up

[BK @bk7gems]

Three weeks ago Trump signed a law giving himself the power to hit countries with tariffs as high as 100 percent simply for buying Russian oil and gas. India and China were the obvious targets. The message was clear: anyone else purchasing Russian energy was undermining American pressure on Moscow and would pay for it.

Yesterday he announced a deal with Putin for Russia to start shipping diesel straight into the American and global market. The numbers he put out were 300,000 tonnes immediately, another 500,000 tonnes in November, 1 million tonnes right after that, and potentially 3 million more once Russian refineries can deliver. The Treasury promptly issued a temporary license so the cargoes can move.

Diesel in the United States is still sitting near $6.28 a gallon. Midterm elections are 24 days away. The same administration that spent months threatening secondary tariffs on buyers of Russian energy has now arranged for Russian diesel to reach American pumps under an official exemption. Ukrainian officials called the arrangement a gift that helps Putin keep funding the war. Analysts note the volumes are unlikely to move prices much in the short term.

The contradiction does not require interpretation. The tariff authority was exercised against others. The purchase is now being arranged for the United States. Both actions occurred inside the same month.

[BK @bk7gems]

Elon, the “Dear Prime Minister Ambani” note was not clever. It was unnecessary and sooo not you. You spent years in India’s licensing queue, same as OneWeb and Jio Satellite, all of you waiting on security clearance and spectrum, and the moment it did not move yet, you make nasty comments choosing time wisely trying to blackmail a country. That is bad taste. It is also a convenient story for a man who wants the Indian market but keeps praising China while having no access there.

Countries do not hand over satellite communications because a foreign owner tweets about children and small shops. Low-earth-orbit networks carry traffic, can be steered, and answer to the laws of the place that owns them. India is running the same security screen it runs on everyone else. You call the delay a crime and a monopoly chokehold. The government has already said the framework is the same for the applicants in the queue. Name-calling is not evidence. Your service is mostly unaffordable and your father can choose when to turn it off.

There is also the small matter of who can switch you off. Starlink is an American company. It lives under US export rules, sanctions law and whatever direction Washington feels like giving that week. America has spent the last few years turning chips, payments, clouds and cables into leverage, aimed at rivals and sometimes at partners who will not fall in line. A network that can be throttled or redirected from outside the country is not a gift. It is a dependency. For any state that has watched how fast American policy flips, that dependency is a security question, not a footnote. You sell the service as rescue. The rescue comes with a foreign kill switch.

And then there is China, which you treat like a favourite uncle. Tesla’s biggest factory sits in Shanghai. You praise the speed, the workers, the regulators, the future. You stay carefully quiet about the part where foreign brands spent decades being copied, squeezed, forced into joint ventures and then watched their technology walk out the door. Whole sectors were closed or tilted until the local champion was ready. Cars, telecom gear, solar, high-speed rail, software. The pattern is not subtle. Starlink itself is not welcome there. None of that seems to trouble you. No open letters. No “real boss of China” jokes. No lectures about monopolistic exploitation of the Chinese people. The praise keeps flowing, because the factory keeps running and the market is too large to offend.

So the sermon about Indian oligarchs and denied schoolchildren lands a little flat. You accept hard barriers, tech transfer and political deference when the counterparty is Beijing. You reach for sarcasm and moral outrage when the counterparty is Delhi and the licence is still in review. That is not principle. That is a salesman annoyed that one door is slower than the other. India can weigh the coverage gaps against the control risk and the precedent. It does not owe you a shortcut because you have decided Ambani is the plot and China is the partner.

[BK @bk7gems]

@elonmusk @EPortmanager Would love to use it in China 🇨🇳

[BK @bk7gems]

Parag Milk Foods (Q2 FY26) hit a major milestone with quarterly revenue crossing ₹1,000 Cr for the first time (₹1,008 Cr, +16% YoY). Profit after tax jumped 56% YoY, and net debt dropped ₹125 Cr to ₹436 Cr. Strategic momentum is clearly building.

what’s driving it👇

📌 Revenue & Profitability
•H1 revenue: ₹1,859 Cr (+14% YoY), with Q2 seeing 10% volume growth
•EBITDA ₹89 Cr (+16% YoY), margin stable at 8.9%
•Net profit sharply up; margin held despite milk inflation (+16% YoY)

💰 Cash & Capital
•Operating cash flow (H1): ₹99 Cr
•Net debt/EBITDA now at 1.4x; Net debt/equity at 0.4x
•Deleveraging aided by FCCB conversion + equity raise

🧃 Category Mix & Growth
•Core categories (ghee, cheese, paneer): 59% of revenue, volume +14% YoY
•“New Age” (Avvatar Whey + Pride of Cows): +79% YoY, now 9% of turnover
•Route-to-market mix: B2C ~70%, B2B ~30%

🧬 Health & Nutrition Pivot
•Goal: ₹10,000 Cr revenue in 3–5 yrs
•Cheese growth aligned to whey production → Avvatar
•Launches: Fuel Whey, Performance Whey, Protein Wafer Bars
•Vision: 20% of future portfolio from health & nutrition
•On Amul’s entry in protein: “No impact… may help educate the market”

🥛 Pride of Cows
•Now in 8 cities incl. Chandigarh; scaling via Q-commerce
•Strong brand positioning: “What’s the Source?” + influencer campaigns

🧾 Brand & Channel Push
•Continued B2C mix expansion; cheese moving from HoReCa to consumer
•29 depots pan India
•Partnered with Kaun Banega Crorepati, Super Dancer, regional news media

📈 Margins & Efficiency
•Reported EBITDA: 8.9%
•Core EBITDA (ex-other income): 7.1%
•PAT growth ex-other income: 114%
•Cost controls, mix, and channel shift driving operating leverage

🏛 Governance & Structure
•New board, Deloitte as internal auditor
•Key hires across GT, MT, HoReCa, liquid milk, Pride of Cows, Avvatar
•Focused execution after legacy write-offs

📊 Incentives & Cash Utilization
•FY25 state incentives: ₹85 Cr (milk subsidy + SGST-linked)
•Expected to continue for 7-8 years at reduced pace
•OCF primarily funding capex and interest

🔎 Execution Watchlist
•Avvatar launches & pricing post-GST
•Pride of Cows city rollouts & premium growth
•B2C mix > 70%, New Age >10% of revenue
•Procurement scale up (15 → 40 lakh L/day); higher BMC share
•Core EBITDA trajectory toward 2-digit zone

🎯 Bottom Line
PMFL is not just scaling, it’s transforming! With brand pricing power, rising B2C salience, a protein led health pivot, and tight cost control, the path to ₹10,000 Cr topline and double digit margins looks increasingly credible. Invest wisely! DYDD!

[BK @bk7gems]

… continued from previous post

Next-tier names sit below the large custom-synthesis and sterile players. They are smaller, often higher-margin, and more exposed to early-to-late programmes in peptides, ADCs, complex intermediates and contrast media. Figures are FY26 unless noted.

Sai Life Sciences: Fully CRDMO. FY26 revenue ₹2,192 cr (+29%), EBITDA ₹661 cr (30% margin), PAT ₹355 cr (+109%). Mix was CDMO ₹1,417 cr (65%, +33%) and CRO ₹775 cr (35%). Works with 19 of the top 25 global pharma companies; large-pharma share rose to 49% of revenue from 28% in FY22. Pipeline has 155 development programmes, 33 commercial molecules and 14 late-phase assets. Capex was ₹633 cr. Building peptide, oligonucleotide and ADC-related small-molecule capability. Growth is tied to large-pharma outsourcing rather than one blockbuster intermediate contract.

Anthem Biosciences: CRDMO was ~83% of FY26 revenue of ₹2,124 cr (+15%); specialty ingredients the rest. EBITDA margin ~39–43%, PAT ₹592 cr. More than 100 early-stage programmes and 10 Phase-3 molecules spanning ADCs, peptides, oligos and biotransformation. Commercial molecules (including four new launches) were ~60% of revenue. Fermentation capacity of 142 kl sits with 425 kl of custom synthesis; a third site is adding peptide and oncology work. Management has cited competitive cost of goods on GLP-1-type peptides and an ADC payload platform covering 15–20 varieties. Order-book visibility has covered a majority of near-term CRDMO targets. Highest margins in the set; revenue can swing with delivery timing.

Blue Jet Healthcare: FY26 revenue ₹947 cr (down 8%). Contrast-media intermediates were the larger growth piece (~₹495 cr in that segment on some disclosures) with pharma intermediates/APIs the balance and sweeteners smaller. Guides double-digit contrast-media growth in FY27 on 3–4 new launches and an iodinated intermediate, and aims to recover pharma-intermediate sales toward the prior peak as destocking ends. Tracking ~20 CDMO RFPs and four programmes in oncology, CNS and other chronic areas. EBITDA margin around 30%. Niche intermediates plus an emerging CDMO book, not large peptide or ADC scale yet.

Shilpa Medicare: Group revenue ~₹1,535 cr, with oncology APIs ~47%, formulations ~42% and biologics ~11%. Shilpa Biologicals has commissioned a GMP ADC drug-substance facility in Dharwad covering payload, linker, mAb and conjugation—one of the few integrated Indian ADC sites. Longer history is in high-potency oncology APIs. ADC and biologics capacity are still ramping, so contribution to group numbers remains limited.

Jubilant Pharmova: Larger group base, with contract share cited near 36% of roughly ₹8,300 cr. Relevant pieces are CDMO sterile injectables and a CRDMO arm rather than a pure peptide or ADC play. Adds scale in sterile formats but less direct leverage to oral-GLP intermediates or ADC payloads than Sai Life or Anthem.

Concluding: Sai Life and Anthem are the clearest next-tier beneficiaries of multi-modality outsourcing, with Anthem carrying higher margins and Sai Life stronger large-pharma revenue growth. Blue Jet is a contrast-media and intermediate specialist with a smaller CDMO option. Shilpa’s ADC suite is a capability bet still early in commercial contribution. None yet matches Divi’s disclosed intermediate volumes.

[BK @bk7gems]

Indian CDMOs capturing global innovation work cluster around peptides/GLP-1 intermediates, ADC payloads & conjugation, complex small-molecule custom synthesis, & sterile injectables.

Divi’s: Custom synthesis is ~55–60% of rev. FY26 rev ~₹10,400 cr (+13%), PAT ₹2,607 cr. Manufacturing two advanced intermediates for a small-molecule oral GLP drug (Jefferies models up to ~$630 mn annual rev by FY32 on partial use of 300 Mt capacity) & in tech transfer for peptide fragments of an injectable GLP (potential ~$426 mn by FY32). Dedicated peptide facility operational; capex > ₹1,500 cr in FY26. Highest scale & margin profile among pure custom-synthesis names; GLP volumes are the main incremental driver.

Laurus: CDMO share rose from ~30% in FY26 toward the low-40s early in FY27, targeting 50% by FY30. FY26 rev ~₹6,800 cr. Growth from late-stage small-molecule projects, flow chemistry and biocatalysis; 100+ active CDMO projects and expanding fermentation capacity. Less direct GLP peptide exposure than Divi’s, but benefits from complex chemistry shifting out of China.

Piramal Pharma: CDMO is roughly half of group TO (group ~₹8,900 cr in FY26). Offerings include integrated ADC work (payload-linker plus bioconjugation, including UK suites), high-potency APIs & sterile products. Jefferies cites ADC as one of the fastest-growing segments (~12–15% of the CDMO division) & names it among the few Indian integrated ADC players. Commercial projects with multiple large pharma clients already running.

Cohance: FY26 rev ~₹2,270 cr, with pharma CDMO a material but variable share. Strength in ADC payloads (MMAE-related chemistry covering a large part of the clinical pipeline) after the NJ Bio acquisition, plus specialty intermediates. Pipeline exceeds 140 projects, with several molecules moving to commercial supply; quarterly phasing can be lumpy.

Neuland Laboratories: Custom manufacturing ~60–67% of rev; FY26 rev ~₹2,000 cr. Commissioning commercial-scale peptide capacity (solid & liquidphase) with early client commitments & partnering with Gland on sterile APIs for complex injectables. Relevant for peptide fragments & high-complexity small molecules.

Syngene: Essentially 100% CRDMO. FY26 rev ~₹3,740 cr, research services (~78%) with manufacturing the balance. Benefits from China+1 pilots converting to longer contracts across small molecules & biologics; growth steadier but lower-margin than pure commercial custom synthesis.

Gland Pharma: CDMO (sterile injectables) approaching half of rev; FY26 rev ~₹6,400 cr. Exposure mainly fill-finish and complex injectables rather than drug substance. The Neuland sterile-API partnership adds drug-substance angle for depot & specialty injectables.

Concord Biotech: Specialist in fermentation-based APIs (immunosuppressants such as tacrolimus and mycophenolate, plus anti-infectives and oncology). FY26 rev fell 12% to ₹1,055 cr on supply disruptions; Q1 FY27 rev recovered 26% to ₹257 cr, with API growth of 42%. True third-party CDMO (innovator IP) is only 1–2% of sales; Mgmnt targets a double-digit contribution & has commercialised at least one project, with others in advanced discussion. U-3 (Limbasi) has ~800 m³ fermentation capacity, with rev potential cited near ₹1,200 cr at higher utilisation. Antique estimates the CDMO opportunity at roughly ₹400 cr over 3–5 years. High EBITDA margins (mid-30s) & fermentation entry barriers are strengths, but it is not yet a scaled beneficiary of GLP-1, ADC or peptide outsourcing; upside depends on converting fermentation CDMO discussions.

Largest near-term GLP/peptide leverage sits with Divi’s, followed by Neuland. ADC leverage is clearest at Piramal & Cohance. Broad complex-chemistry & China+1 exposure is widest at Laurus, Divi’s & Syngene. Concord is a high-margin fermentation pure-play whose CDMO optionality is still early-stage & small relative to the others. Revenue mixes & project timing remain the main variables that move earnings from these themes.

[BK @bk7gems]

Orforglipron (branded Foundayo) is Eli Lilly’s once-daily oral small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes. Unlike peptide injectables such as tirzepatide (Mounjaro/Zepbound), it is made through multi-step chemical synthesis, so the relevant outsourcing is of complex intermediates and potentially API or finished dosage form rather than peptide fragments.

Lilly has committed more than $1 billion to contract manufacturing partnerships in India, is embedding its own teams with local partners, and has stated that Indian production partners are already supporting global supply for its portfolio, with orforglipron volumes expected to scale once approvals and launches progress (US approval occurred in 2026; Indian launch is projected around 2027 subject to regulatory clearance).

Divi’s Laboratories is the company most frequently cited by analysts as positioned for this opportunity. Jefferies has noted that Divi’s is manufacturing two advanced chemical intermediates for a small-molecule oral GLP drug, with capacity of 150 metric tonnes per intermediate (300 tonnes combined). The brokerage models potential revenue of roughly $630 million by FY32 from this contract alone under partial utilisation assumptions, citing the chemical complexity (chiral molecules, regio-selectivity and steric constraints) that supports premium pricing. Separately, Jefferies flags Divi’s as a likely beneficiary of Lilly’s India supply-chain investments because of its existing Big Pharma relationships and custom-synthesis capabilities, though any Lilly-specific volumes were not included in the base-case estimates. Management commentary has also referenced small-molecule and GLP-1-related work alongside peptide capacity expansions.

Other Indian CRDMO and specialty chemical players that could benefit, based on technical fit and prior analyst commentary around Lilly’s broader $1 billion India programme, include:

1) Laurus Labs and Neuland Laboratories, both of which have established strengths in complex multi-step synthesis, chiral chemistry and regulated-market custom manufacturing that align with oral small-molecule intermediates.

2) Syngene International and Piramal Pharma Solutions, which offer integrated CRDMO services (process development through commercial manufacturing) and have been named among firms that gained credibility with global innovators on quality and compliance.

3) Secondary opportunities could extend to packaging, analytical testing and logistics partners once commercial volumes rise, though these are lower-value relative to the intermediates themselves.

No company has been officially named by Lilly as an orforglipron intermediate supplier, and the firm has partnerships in China (including a reported Pharmaron collaboration) as well as its own new plants in the US and Europe. The Indian opportunity therefore remains capacity- and relationship-driven rather than confirmed contract awards. The highest-conviction near-term name in public research remains Divi’s because of the documented oral GLP intermediate work and the explicit linkage drawn by analysts to Lilly’s India manufacturing push.

[Amit Multibagger Stocks @1big_bull]

Electrical Connectivity - Sterlite Technologies and HFCL

Precision Engineering- MTAR Tech, Sansera engineering, Azad Engineering, Omnitech, Aequs

Pharma / CDMO - Morepen lab, Sakar Healthcare , Aarti Pahrma, Shilpa Medicare, Sai Life, Laurus Lab, Kwality Pharma, Gland Pharma, Sudeep Pharma, Acutaas, Divis lab, Beta Drugs, Neuland

Consumer and Consumer Tech – Cupid, Timex, Ethos, Milky Mist, Shadowfax technology, HOAC Foods

Jewellery- Deepa Jewel, Lalithaa Jewel, AJC Jewel, Sky Gold, Titan, Kalyan, PN Gadgil, PNGS Reva

Cooling – KRN Heat Exchanger, Aeroflex

Capital Goods - Welspun Corp, Man Industries

Auto and Auto ancillary - Sedemac Mechatronics, Ather Energy, Lumax Auto Tech, SJS, Divgi torq, Craftsman Automation, Uno Minda, Sona BLW, Bosch, Gabriel India, TVS Motor Bajaj Auto, Rolex rings, OBSC Perfection, Pricol, Steel Strips

GPUs, Supercomputers- E2E networks, Netweb

Power Infrastructure - TD Power Systems, GE Vernova T&D, Yash High voltage, Pitti Engineering, Kirloskar Oil Engines, ABB India, Siemens India, Siemens Energy, Schneider Electric, Hitachi Energy India, Cummins India, CG Power, Quality Power

Cables– Prime Cable, VMarc, Dynamic cable, RR Kabel, KSH International, Finolex, Universal Cable, Polycab

[Intrinsic Compounding @soicfinance]

Good update by Sambhv with more than 25%+ Volume growth on a YOY basis.

Steel tubes and Pipes continue to do well

Disc: no reco to buy or sell.

[ميد | MED💉🎓 @Medical_MD1]

Lung Sounds 🩺 🫁

.

[Normal Guy @Normal_2610]

SEDEMAC makes tiny computer chips that go inside engines, generators, and motors But chips are not why this company is valuable

Software running on those chips is why. SEDEMAC writes programs that control how fast engines run, when generators start, and how motors respond to heat and weight. Once vehicle makers test this software and approve it, they do not switch easily.

Retesting costs time and money. SEDEMAC has 12 patents on this technology. 80%+ of new ISG chip growth in India last year came from SEDEMAC alone

SEDEMAC used to make most of its money from engine and generator controllers. Revenue from EV motor controllers changed that picture in FY26.

EV controller revenue went from ₹10 Cr to ₹68 Cr in 12 months. SEDEMAC now has 1 million electric 3-wheeler controllers running on Indian roads. It took 28 quarters to get there. But 2-wheeler EVs are growing even faster now.

SEDEMAC already supplies engine chips to 35% of India 2W and 3W market. Same factory, same customers, new product line. Generator profits pay for this EV push

SEDEMAC earned ₹1,058 Cr in FY26. That is 61% more than FY25. Company makes controllers for generators and engines. In generators alone, SEDEMAC controls 75% of Indian market and 14% of global market.

It sold nearly 4 million controller chips last year, with lifetime total crossing 12 million units. Company is now almost debt-free. For every ₹100 of capital invested, SEDEMAC earns ₹40 back. In Q1 FY27, profits nearly doubled compared to same quarter last year.

Generator business keeps printing cash that cash is going into building EV controllers next

One of the top performer IPO of 2026 after ESDS

[R'izwan | Capital Edge @Riz_Capitaledge]

📈 20 stocks hitting fresh ALL-TIME HIGHS!

SEDEMAC Mechatronics — 3,444.90
Antelopus Selan Energy — 1,261.70
Hero Motors — 141.69
Aether Industries — 1,767.00
Man Industries — 1,020.35
Pearl Global Industries — 1,329.10
Dynamatic Technologies — 13,153.00
Engineers India — 315.65
Aimtron Electronics — 1,890.25
Shreeji Shipping Global — 752.45
Spectrum Electrical — 3,518.80
Steelcast — 376.50
Prasol Chemicals — 756.00
Kabra Extrusiontechnik — 846.40
Bhageria Industries — 394.60
Utsav CZ Gold Jewels — 722.10
STL Networks — 54.61
Shanti Gold International — 325.68
SBC Exports — 53.02
Anlon Healthcare — 31.51

#AetherIndustries #EngineersIndia #SEDEMAC #PearlGlobal #ShreejiShipping #DynamaticTechnologies #ManIndustries #HeroMotors #SpectrumElectrical #PrasolChemicals #SelanEnergy #AimtronElectronics #Steelcast #KabraExtrusiontechnik #STLNetworks #SBCExports #ShantiGold #UtsavCZGold #BhageriaIndustries #AnlonHealthcare

[Meyyappan PL @MeyyappanPl1]

RPG life science

Carved out Standalone API vertical RPG active pharma limited

InvAscent invested 243cr for 40% stake

700cr set aside for inorganic growth opportunities

Acquired 2 units

-Active generic pvt limited for 85cr
-Raghava life science for 135cr

They increased Capacity, R&D & pipeline products

[BK @bk7gems]

Dear President Trump, It’s Syntelligence. Not #AI. Not Artificial Intelligence. Not Super Intelligence for sure.

We keep calling these systems “artificial”. They are not. They do not pretend to be human. They ingest, compress, recombine and generate across every domain we have ever recorded.

That is synthesis, not imitation. The word we needed was never “artificial.” It was #Syntelligence: intelligence that works by bringing together what evolution scattered across millions of years and billions of brains.

Artificial Intelligence was a 1950s slogan. Useful then. Misleading now. #SuperIntelligence is the wrong horizon too. Super Intelligence arrives the day we can recreate life itself across evolutionary biology, when a system can start from chemistry, run selection, invent metabolism, invent death, invent sex, invent language, and keep going without us. That is not next year. That is not even next decade. That is a civilizational threshold.

What we have today sits in the middle. It is not alive. It does not suffer. It does not want. It synthesizes. It finds the pattern that no single human lifetime could hold. It writes the paper, designs the molecule, maps the supply chain, and still cannot feel the rain.

That gap is the point. Call it what it is.
Syntelligence is the name for systems that compound knowledge faster than biology compounds genes, without crossing into organisms. Use it when the model is doing work no single mind could do. Stop saying the old labels as if the category is settled.

The category is open. The next fifty years will be spent deciding how far synthesis can go before we have to admit we built something that is no longer just a tool.
Super Intelligence is the recreation of life. Syntelligence is everything we build until that day. The distinction matters. Words shape what we fund, what we fear, and what we allow.

It’s SYNTELLIGENCE.

#Syntelligence #POTUS #ElonMusk #Elon #MrTrump #UN #UnitedNations #NewWord #TechPolicy #FutureOfIntelligence #LanguageMatters

[BK @bk7gems]

Veefin up 16% yesterday 💪👏👏

[BK @bk7gems]

Will this change now??? Which stocks will benefit??? 🤷‍♂️

China’s economic rise has been heavily built on an investment- and export-led model rather than domestic consumption.

Household consumption in China accounts for approximately 40 percent of its gross domestic product in 2024, which is substantially lower than the global average of roughly 63 percent and the United States at about 68 percent. Seminal research into the China Shock by economists David Autor, David Dorn, and Gordon Hanson demonstrates that rapid Chinese import penetration led to the loss of approximately 2 to 2.4 million manufacturing jobs in the United States between 1999 and 2011, severely impacting Western industrial hubs.

Analysis from the Center for Strategic and International Studies confirms that China allocates roughly 1.73 percent of its gross domestic product to industrial policy spending and subsidies, a rate far exceeding other major economies. Furthermore, investigations by the US Trade Representative have detailed widespread intellectual property theft and forced technology transfers, which have collectively reshaped global manufacturing and now extend into critical frontiers like artificial intelligence and advanced semiconductors.

In parallel, the United States has heavily relied on its financial dominance and the petrodollar system established in the 1970s. The Federal Reserve aggressively expanded the money supply through quantitative easing, causing its balance sheet to swell from less than 1 trillion dollars before the 2008 crisis to a peak of nearly 9 trillion dollars following the pandemic. This massive liquidity injection created global inflationary pressures. To defend the dollar’s hegemony, the United States has deployed extensive financial sanctions against countries like Iran and Venezuela that challenge the dollar-centric financial architecture, leading to prolonged geopolitical stalemates.

Regarding India’s positioning, the economic divergence with China became particularly pronounced in the 2000s. While India recorded some of its highest historical economic growth between 2002 and 2008, with annual gross domestic product growth averaging around 8 percent, China utilized its 2001 World Trade Organization entry to scale exponentially.

In the year 2000, China’s economy was valued at approximately 1.22 trillion dollars while India’s stood at 468 billion dollars. By 2010, China had scaled to over 6.1 trillion dollars compared to India’s 1.68 trillion dollars, widening the economic ratio from about 2.6 times to nearly 3.6 times. While India grew rapidly during the mid-2000s, it lacked the state-directed, large-scale infrastructure and manufacturing policies that allowed China to pull away so decisively.
To counter this historical imbalance, India has aggressively scaled up its infrastructure and domestic production capabilities over the last ten years. Capital expenditure in the central budget has risen dramatically, increasing from around 2.5 lakh crore rupees in fiscal year 2015 to over 11 lakh crore rupees in recent budgets.

The implementation of the Production Linked Incentive schemes, with an outlay of nearly 1.97 lakh crore rupees, approximately 24 billion dollars, across 14 key sectors, represents a major structural push to revive domestic manufacturing. Navigating the current geopolitical landscape involves complex trade-offs, forcing India to practice strategic autonomy by balancing vital energy and defense ties with Russia while simultaneously strengthening the Quad alliance with the United States, Japan, and Australia to counter regional imbalances.

This framework underscores clear opportunities for India-centric supply chain strategies in manufacturing and infrastructure, enabling sharper risk mitigation in global operations while highlighting the need for vigilant monitoring of subsidy distortions and geopolitical flashpoints that could reshape competitive edges.

[BK @bk7gems]

Small-cap Indian stocks with multibagger potential in defence, AI/tech enablers, EMS/picks-and-shovels, specialty chemicals, consumer, and related themes. These are high-risk speculative ideas tied to India’s defence indigenization, PLI schemes, electronics manufacturing, capex, AI/data centre growth, specialty chemicals for industry, and consumer sectors as of late May 2026.
Long-term horizon (3-7+ years) needed.

Paras Defence and Space Technologies: Optics, electronics, space and defence systems. Niche player with growth in orders. Market cap 6,000-6,500 Cr.

Data Patterns (India): Defence electronics subsystems with high indigenous content. Rapid order book expansion. 22,000 Cr.

MTAR Technologies: Precision engineering for defence, nuclear, space, and aerospace. Strong thematic exposure and past growth. Market cap in higher small to mid range.

Rossell Techsys: Aerospace and defence electronics, wiring harnesses. Smaller cap with niche overlap.

Sika Interplant Systems: Aerospace and defence components and systems. Very small cap.

NIBE Ltd: Defence platforms, precision components, EVs, and artillery-related expansions. Market cap around 1,500-2,100 Cr.

Krishna Defence and Allied Industries: Defence products manufacturing along with allied kitchen and dairy equipment. Market cap 1,600-1,700 Cr.

Aimtron Electronics: Electronics system design and manufacturing (ESDM/EMS) for defence, drones/UAVs, EVs, IoT, robotics, AI applications, and industrial. Recent strong revenue growth, order wins in IIoT/AI surveillance, and ODM shift. Market cap 2,300-2,350 Cr.

Veefin Solutions: Digital lending and supply chain finance technology solutions for banks/NBFCs. Fintech play with AI-adjacent tools. Market cap around 850-870 Cr.

Freshara Agro Exports: Food processing and exports of preserved gherkins, pickles, and related products. Export-focused but limited direct defence/AI overlap. Micro/small cap 490-500 Cr.

Parag Milk Foods: Dairy processing and milk products company with consumer FMCG focus, ghee, paneer, and value-added items. Benefits from organized dairy growth and exports. Small cap with market cap around 2,600-2,650 Cr.

RateGain Technologies: AI-powered SaaS platform for travel and hospitality personalization, revenue management, and distribution. Strong growth in contract wins and data capabilities. Market cap 8,400 Cr .

Aether Industries: Specialty chemicals and advanced intermediates for pharma, agro, and industrial applications. Differentiated chemistry with growth in high-value products. Market cap 13,950 Cr.

Cyient DLM: Electronics manufacturing services with defence and aero focus.
Avalon Technologies: Specialized EMS and components for various sectors.

Syrma SGS Technology: EMS and PLI beneficiary for electronics and components.
MosChip Technologies: Semiconductor design and IP.

MIC Electronics or SPEL Semiconductor: Niche semiconductor/OSAT plays (higher risk).

Netweb Technologies: AI/HPC servers and data centre solutions.

MIRC electronics?? Turnaround bet?? Leadership monitoring at MIRC and Parag milk foods suggests they could be potential multi-baggers.

Additional mentions in the space often include smaller EMS/component names or precision plays that tie into defence electronics, data centres, manufacturing shifts, and specialty chemicals supporting broader industrial growth.

Key risks: Stretched valuations in hot themes, dependency on government orders and policies (especially defence/PLI), execution challenges, global competition, rupee moves, commodity/input costs (for chemicals/dairy), and sharp corrections possible in small-caps.

Focus on companies showing consistent revenue/profit growth, healthy order books (where applicable), and alignment with Atmanirbhar Bharat, PLI, China+1, and domestic consumption trends. Diversify and track quarterly results closely.

[BK @bk7gems]

#UStariffs Update. The House passed the bill 262 to 159 on September 16. It now sits on the President’s desk. Trump has said he will sign. Until he does, Day 0 has not started. Then the 30 day clock starts ticking for countries like India and China.

After signature:- Within 30 days, duties on goods from Russia can rise as high as 500%. Separately, the President can put extra duties of 0% to 100% on all U.S. imports from countries that stay among the top buyers of Russian oil or gas, or that help move the shadow fleet. India and China are the most exposed. Turkey, the UAE, Singapore, Kazakhstan and Azerbaijan could follow. Some European gas buyers may get a carve-out if they keep cutting volumes. Customs would apply any new duty only after a public notice, not to old shipments. The earliest realistic window is still late October 2026.

The signature is now a political and price decision, not only a Russia decision.

Tariffs on Indian and Chinese goods would not hit Russian crude first. They would hit what Americans actually buy: phones, medicines and bulk drugs, apparel, chemicals, auto parts, furniture and machinery. That is how secondary tariffs work. The extra cost shows up at the U.S. border and then on store shelves. Even a 20% or 30% extra duty on a large share of those imports can add to inflation. A 100% rate would be a shock. Voters feel that as higher monthly bills, not as a foreign-policy win.

Midterms sit right in the middle of the clock. The House leaves town around September 17 and returns November 9 after the elections. If he signs this week, the 30-day watch window runs through mid-October. The first possible tariff notice could land in late October, days before people vote. That timing is tight. A law that looks tough on Moscow in September can look like a price hike in late October.

How the decision likely gets weighed: he has two audiences. One wants maximum pressure on Russia and on India and China for buying its oil. The other wants cheaper groceries, cheaper goods and no last-minute inflation surprise.

He has treated tariffs as leverage more than as a permanent tax. The statute helps that habit. It says he “shall” act, but it lets him pick 0% to 100%. He can sign, start the 30-day clock, publish a low opening rate, threaten a higher one, and keep talks open with New Delhi and Beijing. He can also delay the public notice until after November 9. The law gives him that room.

So the practical bet is not “100% on India the day he signs.” The practical bet is signature for the political win, then a measured first rate, or a delayed notice, if inflation data and midterm risk look ugly.

Countries on the list still have a choice in the next 30 to 60 days: keep buying new Russian barrels and accept the risk, or cut enough to argue they should stay off the list when it is refreshed every 180 days. U.S. importers should plan for a possible late-October surcharge, not for an overnight 100% wall.

[BK @bk7gems]

#UStariffs The Senate already passed it 86–11 on August 7. The House cleared a tight 214–211 rule vote on September 15 and was expected to take the final floor vote today (September 16). If the House accepts the Senate text unchanged, the bill goes to the president. Trump has said he will sign it. As of the latest afternoon reports, that final tally had not yet been published.

If the House fails or amends it, the bill does not become law today. The House is due to recess around September 17 and return November 9 after the midterms, so the next realistic window would be mid-November or later.

Step-by-step if the House passes it today
1:Enrollment (hours to a couple of days)
Clerks prepare the official enrolled bill and send it to the White House.
2:Presidential action (up to 10 days, Sundays excluded)
Trump can sign immediately. A signature makes it law. A veto would send it back; override needs two-thirds of both chambers.
3:Enactment date = Day 0
That date starts several statutory clocks. “Becoming law” is not the same as “tariffs start hitting Indian shipments.”

Two different tariff clocks
A. Tariffs on goods from Russia (primary tariffs)
Not later than 30 days after enactment, the president “shall” raise duties on all U.S. imports from Russia, including oil, gas, coal, and related products, to a rate of up to 500%.
B. Tariffs on goods from countries that buy Russian energy (the India/China tool)
This is the 100% secondary-tariff authority.
A country is in scope if it:
•was among the five largest importers of Russian crude or Russian natural gas in the 12 months before the law was enacted, and
•knowingly made new purchases of Russian crude or gas on or after day 30 after enactment
or it is among the five largest facilitators of oil-sanctions evasion.
The statute also says that, not later than 30 days after enactment, the president “shall” increase duties on all goods from those described countries to a rate of up to 100%.

In practice that means:
•Days 0–30: administration identifies the top-five list and watches whether those countries keep buying.
•After day 30: new purchases can lock a country into eligibility.
•The rate is not automatically 100%. The president picks a number from 0% to 100%.
•There is a gas carve-out: countries that take less than 15% of Russia’s gas exports and are taking “significant steps” to cut those imports can be spared. That is aimed more at some European buyers than at India.

C. Refresh every 180 days
Not later than 180 days after the first duties are imposed, and every 180 days after that, USTR (with State and Energy) must redo the top-five list using the most recent 12 months of data and apply duties again. A country can fall off or be added later.

D. Other sanctions (officials, banks, shadow fleet, Iran extension)
Many of those designations also run on a 30-day clock after enactment, then periodic 180-day reviews. Those are separate from the India-export tariff.

Practical timeline for India if the bill is signed this week

Day 0
Law takes effect. No new India tariff yet.

Days 1–30
White House/USTR build the top-five list from the prior 12 months. India is widely expected to be on it because of the scale of its Russian crude buys.

Day 30 onward
If India keeps making new Russian oil/gas purchases, it can meet the second test. The president can then set an extra duty of 0–100% on Indian goods entering the U.S.

~Day 30–60
First possible public tariff announcement and Federal Register notice. Customs would apply it to goods entered after the effective date in that notice, not retroactively to old shipments.

Every 180 days
List and rates can change.
So even in the fastest case (House pass today + signature this week), the earliest realistic window for a new India-specific duty is roughly late October 2026, and only if New Delhi is still buying Russian barrels after the 30-day mark and the White House chooses to use the tool at a high rate.